openPR Logo
Press release

Soft Tissue Sarcoma Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)

10-12-2023 10:42 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Soft Tissue Sarcoma Pipeline

Soft Tissue Sarcoma Pipeline

DelveInsight's, "Soft Tissue Sarcoma Pipeline Insight 2023" report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Soft Tissue Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Soft Tissue Sarcoma Pipeline Report
• DelveInsight's Soft Tissue Sarcoma pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Soft Tissue Sarcoma treatment.
• The leading companies working in the Soft Tissue Sarcoma Market include Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, and others.
• Promising Soft Tissue Sarcoma Pipeline Therapies in the various stages of development include Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, and others.
• September 2023: Chipscreen Biosciences Ltd announced a study of phase 2 clinical trials for Chiauranib. This is a Phase 2, single-arm, open-label study in patients with advanced or unresectable soft tissue sarcoma.
• September 2023: Lyvgen Biopharma Holdings Limited announced a study of phase 1 & 2 clinical trials for LVGN6051 and Anlotinib. The purpose of this study is to asess the safety and tolerability and efficacy of LVGN6051 combined with anlotinib in patient with soft tissue sarcoma.

Request a sample and discover the recent advances in Soft Tissue Sarcoma Treatment Drugs @ Soft Tissue Sarcoma Pipeline Report- https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Soft Tissue Sarcoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Soft Tissue Sarcoma Overview
Soft tissue sarcoma is a disease in which malignant (cancer) cells form in the soft tissues of the body. Having certain inherited disorders can increase the risk of soft tissue sarcoma. A sign of soft tissue sarcoma is a lump or swelling in soft tissue of the body. Soft tissue sarcoma is diagnosed with a biopsy. Soft-tissue sarcomas are a group of cancers that begin in the connective tissues that support and connect the body, including: Blood vessels, Fat cells, Lining of joints, Lymph vessels, Muscle, Nerves and Tendons.

Find out more about Soft Tissue Sarcoma Therapeutics Assessment @ Soft Tissue Sarcoma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Soft Tissue Sarcoma Emerging Drugs Profile
• AL3818: Advenchen Laboratories
• L19 TNF: Philogen
• Camsirubicin: Monopar Therapeutics

Soft Tissue Sarcoma Pipeline Therapeutics Assessment
There are approx. 125+ key companies which are developing the Soft Tissue Sarcoma therapies. The Soft Tissue Sarcoma companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories, LLC.

Soft Tissue Sarcoma Pipeline Segmentation
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Soft Tissue Sarcoma Report Assessment
• Soft Tissue Sarcoma Pipeline Product Profiles
• Soft Tissue Sarcoma Therapeutic Assessment
• Soft Tissue Sarcoma Pipeline Assessment
• Inactive drugs assessment
• Soft Tissue Sarcoma Unmet Needs

Learn more about the emerging Soft Tissue Sarcoma Pipeline Therapies @ Soft Tissue Sarcoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Soft Tissue Sarcoma Pipeline Report
• Coverage- Global
• Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Soft Tissue Sarcoma Companies- Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, and others.
• Soft Tissue Sarcoma Pipeline Therapies- Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, and others.

Dive deep into rich insights for new drugs for Soft Tissue Sarcoma Treatment, Visit @ Soft Tissue Sarcoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Soft Tissue Sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Soft Tissue Sarcoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Anlotinib: Advenchen Laboratories, LLC
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Camsirubicin: Monopar Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. FHD-609: Foghorn Therapeutics
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Soft Tissue Sarcoma Key Companies
18. Soft Tissue Sarcoma Key Products
19. Soft Tissue Sarcoma- Unmet Needs
20. Soft Tissue Sarcoma- Market Drivers and Barriers
21. Soft Tissue Sarcoma- Future Perspectives and Conclusion
22. Soft Tissue Sarcoma Analyst Views
23. Soft Tissue Sarcoma Key Companies
24. Appendix

For further information on the Soft Tissue Sarcoma Pipeline therapeutics, reach out to Soft Tissue Sarcoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Soft Tissue Sarcoma Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated) here

News-ID: 3246914 • Views:

More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical Stage Assets, Pharma Collaborations, Regulatory Developments, and the Global Market Growth Prospects
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Current Drug Trials, Potential Breakthrough Therapies, Pharma R&D Initiatives, and Future Market Transformations
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinical Advances, Pharma Strategies, and Market Evolution
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action, Ongoing Clinical Trials, Pharma Collaborations, and the Future Outlook of the Therapeutics Landscape
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights!

All 5 Releases


More Releases for Soft

Soft Drink Concentrates Market
Introduction The soft drink concentrates market plays a pivotal role in the global beverage industry. These concentrates are primarily used to prepare soft drinks, offering a cost-effective and efficient way for manufacturers to produce various beverages. Soft drink concentrates are essentially flavored syrups or powders that, when mixed with water or carbonated water, create popular soft drinks. The market for these concentrates has seen remarkable growth in recent years, driven by
Soft Robot Technology Market Upcoming Trend & Positions 2027 | Cyberdyne, Soft R …
Soft Robot Technology Market Strengths, Weaknesses, Opportunities, and Threats analysis. Demanding Market Research Report on Global Soft Robot Technology Market conducted by a team of industry specialists. The report covers briefly the products or services in the market and their application. The report also provides data on the technological advancements taking place in the Soft Robot Technology market, helping the market vendors to increase their business productivity and operational efficiency. The
Global Motor Soft Starter Market, Global Motor Soft Starter Industry, Market Rev …
The Motor soft starter has remarkable application in numerous end-use industries like oil & gas, mining and power generation trades. It supports in lessening the inflow current formed whereas motor start up and consequently boost the extending and proficiency of motor. Along with this, it knowingly assistances in governing motor acceleration which outcomes in safety of motor from much impairment while in complete procedure. It is an apparatus that is
Soft Touch Film and Soft Touch Lamination Film Market Size, Share, Development b …
Global Info Research offers a latest published report on Soft Touch Film and Soft Touch Lamination Film Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Soft Touch Film and Soft Touch Lamination Film players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in
Soft Skills Management Market - Increasing Demand For Cloud-Based Soft Skill Tra …
According to a new market report published by Transparency Market Research, the global soft skills management market was valued at US$ 11,289.7 Mn in 2016 and is expected to expand at a CAGR of 11.9% from 2018 to 2026, reaching US$ 33,736.1 Mn by the end of the forecast period. According to the report, the global soft skills management market will continue to be influenced by a range of macroeconomic
Suma Soft
Texas (USA), Canada (Toronto) & India (Business Network)— Suma Soft’s BPO for companies in USA, Canada and UK efficiently streamline business processes. Suma Soft has developed an integrated back-office system that assists these companies giving them round the clock support. Credibility & Certification : Suma Soft is an ISO 27001 and 9001 certified company which gives paramount importance to security, accuracy and quality while delivering BPO support services. We have a